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Leishmania mexicana cysteine peptidases (CPs) have been identified as important parasite virulence factors.
More recently, a natural inhibitor of CPs (ICP) from L. mexicana has been characterized, and ICP mutants
have been created. Infection of BALB/c mice with ICP null mutants or ICP reexpressing mutants resulted in
nonhealing, progressively growing lesions albeit slightly attenuated compared with the growth of lesions
produced by wild-type parasites. In contrast, BALB/c mice infected with mutants overexpressing ICP were able
to significantly control lesion growth or heal. While BALB/c mice infected with wild-type parasites, ICP null
mutants, or ICP reexpressing mutants produced significant antibody responses, including immunoglobulin E
(IgE), no Th1 response, as indicated by antigen-induced splenocyte gamma interferon (IFN-) production,
could be demonstrated. In contrast, BALB/c mice infected with mutants overexpressing ICP produced signif-
icantly less antibody, particularly IgE, as well as significantly reduced splenocyte interleukin-4 and enhanced
IFN- production. BALB/c mice were able to resolve infection following infection with one ICP overexpressing
clone, which was subsequently used for vaccination studies with BALB/c mice. However, no protection was
afforded these mice when they were challenged with wild-type parasites. Nevertheless, two other mouse strains
susceptible to L. mexicana, C3H and C57BL/6, vaccinated with overexpressing ICP mutants were able to control
challenge infection associated with an enhanced Th1 response. This study confirms that L. mexicana CPs are
virulence factors and that ICPs have therapeutic potential.
Leishmaniasis encompasses a large spectrum of clinical dis-
eases which, depending upon the parasite species and the
host’s immune response, can have various outcomes (16). Our
understanding of the factors that lead to this diversity of clin-
ical symptoms has, in large part, come from studies using
murine models and particularly Leishmania major. While the
majority of mouse strains can control infection with L. major,
virtually all develop nonhealing lesions full of parasites when
infected cutaneously with L. mexicana (4). Studies with the
BALB/c mouse have indicated that the nonhealing response of
this mouse strain to infection with L. major is LACK antigen
dependent (13), while the nonhealing response to L. mexicana
is independent of this antigen (27). Conversely, our studies
have implicated cysteine peptidases (CPs) as major virulence
factors for L. mexicana (reviewed in reference 17). Information
about the apparent functions and importance of CPs in the
host-parasite interaction was obtained via the generation of
mutants deficient in the CPA and CPB genes (cpa and cpb
mutants). L. mexicana mutants deficient in the multicopy CPB
gene array (cpb mutants) have reduced virulence, with poor
lesion growth, for BALB/c mice (2, 18). Only the reexpression
of multiple CPB genes from a cosmid significantly restored
virulence (8), suggesting that the multiple genes have comple-
mentary functions. CPA CPB double null mutant parasites
(cpa cpb mutants) were less infective for BALB/c mice than
cpb mutants (2, 18), which not only implicates CPA as a
virulence factor but also indicates that there is some redun-
dancy in function between CPA and CPB. CPA, together with
CPB1 and CPB2 (the CPB isoforms encoded by the first 2
genes of the 19-gene CPB tandem array), is expressed in me-
tacyclic promastigotes, suggesting roles for these CPs in the
virulence of this life cycle stage. Indeed, the L. mexicana cpa
cpb mutants are defective in metacyclogenesis, due to an
impairment of autophagy-dependent protein turnover re-
quired for differentiation (28).
Small-molecule inhibitors of CPB have some efficacy against
Leishmania, both in vitro and in vivo (24). These inhibitors are
thought to be active against not only CPB but also CPA and
CPC, and their toxicity to Leishmania may be a consequence of
the inhibition of multiple enzymes. Nevertheless, these results
confirm the importance of CPs in the host-parasite interaction.
Treatment with a natural CP inhibitor, cystatin, promoted a
protective response against Leishmania infection and a switch
from a predominately Th2 to a Th1 response (7). Leishmania
lacks cystatins, but the parasite possesses an unusual inhibitor
of CPs (designated ICP), which does not occur in mammals
(22). Leishmania ICP has been shown to be a potent inhibitor
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of clan CA, family C1 CPs, such as CPB and mammalian
cathepsin L (22), and the structure has recently been solved by
nuclear magnetic resonance (25). Analysis of L. mexicana mu-
tants lacking ICP implicated the inhibitor in the host-parasite
interaction (3), but whether ICP plays an influential immune
modulatory role awaited examination. The present study used
ICP null mutants (icp mutants), ICP reexpressing parasites in
which ICP had been expressed in the null mutant (icp::PrRNA-
ICP), and null mutant parasites overexpressing ICP (icp[pXG
ICP]) to determine the influence of ICP on the immune re-
sponse and developing disease phenotype. Significantly, while
ICP-deficient parasites remained comparatively virulent, ICP
mutants overexpressing ICP did not promote significant lesion
growth in BALB/c mice and developed a Th1 response. The
vaccine potential of the mutant parasites was subsequently
examined.
MATERIALS AND METHODS
Generation of L. mexicana icp null mutant promastigotes reexpressing and
overexpressing ICP. All ICP transgenic cell lines were generated as described by
Besteiro, Coombs, and Mottram (3). They include two independent ICP null
mutants (icp1 and icp3 mutants), where the two alleles coding for the gene
were replaced by selection markers using homologous recombination. Clones of
the mutants were subsequently used to produce reexpressing cell lines. One had
an integrated single-gene copy at the rRNA locus conferring expression in both
amastigote and promastigote stages of the parasite (i.e., icp::PrRNAICP) and
providing a level of expression of ICP similar to that of wild-type parasites. The
second had extrachromosomal expression of ICP, via the pXG multicopy expres-
sion plasmid, to yield ICP overexpressing cell lines (icp[pXG ICP]).
Culture of mutant parasites. L. mexicana (MNYC/BZ/M379) promastigotes
were cultured at 25°C in modified Eagle’s medium (Invitrogen, Paisley, United
Kingdom) with 10% (vol/vol) heat-inactivated fetal calf serum (Harlan Sera-Lab,
United Kingdom). The appropriate antibiotics were then added to the culture to
select the mutant parasites as previously described (3).
Western blotting. Western blotting was carried out as previously described (3).
Affinity-purified antiserum specific for L. mexicana ICP was prepared as previ-
ously described (22). A 1:1,000 dilution of the affinity-purified anti-ICP antibody
and a 1:10,000 dilution of mouse monoclonal anti-Trypanosoma brucei elongation
factor 1 (Upstate/Millipore) were applied, followed by a 1:5,000 dilution of
secondary antibody conjugated to horseradish peroxidase.
Mice. BALB/c mice were obtained from Harlan UK Limited (Oxon, United
Kingdom) and were bred in-house under barrier conditions. C3H and C57BL/6
mice were purchased from Harlan UK Limited (Oxon, United Kingdom) and
maintained in a specific-pathogen-free environment. Animal experiments were
performed in accordance with United Kingdom Home Office guidelines.
L. mexicana infections. Groups of at least five 6- to 8-week-old female mice
were inoculated subcutaneously with 2  105 to 5  105 stationary-phase pro-
mastigotes grown in modified Eagle’s medium into the hind footpad. The lesion
size was monitored weekly using a sliding-gauge micrometer. Lesions were ex-
cised from L. mexicana-infected mice at the termination of experiments and
disrupted through a metal mesh with 5 ml of RPMI 1640 (Cambrex Bio Science
Verviers, Belgium). The parasites were washed twice at 350  g in RPMI and
enumerated using an improved Neubauer hemocytometer as previously de-
scribed (3).
Vaccination studies. Groups of at least five 6- to 8-week-old female BALB/c,
C3H, and C57BL/6 mice were vaccinated subcutaneously with 2 105 to 5 105
icp1[pXG ICP] or icp3[pXG ICP] parasites into the left hind footpad in RPMI
1640. At 14 weeks postvaccination, mice were challenged with 2  105 to 5  105
wild-type L. mexicana metacyclic promastigotes in RPMI 1640 subcutaneously
into the right hind footpad. The lesion size was monitored weekly using a
sliding-gauge micrometer.
Splenocyte stimulation and cytokine detection. Splenocytes were isolated from
infected mice and cultured for 72 h in 96-well plates in the presence or absence
of L. mexicana antigenic lysate or 0.5 g/ml anti-CD3 (C363.29B; Southern
Biotechnology Associates Inc., AL) as previously described (1, 23). Gamma
interferon (IFN-) levels in the supernatants were detected by capture enzyme-
linked immunosorbent assay (ELISA). Briefly, the wells of Immulon 1B flat-
bottomed microtiter plates (ThermoLabsystems, MA) were coated with 50 l of
1 g/ml purified anti-mouse IFN- capture antibody R4-6A2 (PharMingen;
supplied by Insight Biotechnology, Wembley, United Kingdom) in phosphate-
buffered saline (PBS) (pH 9.0) or 500 ng/ml interleukin-4 (IL-4) capture anti-
body 11B11 (PharMingen) overnight at 4°C. Supernatants were then added to
the individual wells, and either 30 l recombinant mouse IFN- (R&D Systems
Europe, Abingdon, United Kingdom) or recombinant mouse IL-4 (Genzyme,
Cambridge, United Kingdom) was added to individual wells in duplicate in a
doubling dilution with a solution of pH 7.4 PBS supplemented with 10% (vol/vol)
fetal calf serum (Harlan Sera-Lab, Crawley, United Kingdom), ranging from 20
ng ml1 to 0.01 ng ml1 (IFN-) or 2 ng ml1 to 0.977 pg ml1 (IL-4). The plates
were then incubated for 2 h at 37°C. The bound cytokines were incubated with
either biotin rat anti-mouse IFN- monoclonal antibody XMG1.2 (PharMingen)
or biotin rat anti-mouse IL-4 antibody BVD6-24G2 (PharMingen) and detected
with either conjugated streptavidin-alkaline phosphatase or conjugated strepta-
vidin-horseradish peroxidase (PharMingen), respectively. The respective sub-
strate, p-nitrophenyl-phosphate (Sigma-Aldrich, Poole, United Kingdom) or tet-
ramethylbenzidine in pH 5.5 sodium acetate buffer containing 0.0003% hydrogen
peroxide (BDH, Poole), was then added to the wells. Finally, the plates were
read at an absorbance of 405 nm for IFN- or at 450 nm for IL-4.
Detection of L. mexicana-specific IgG1, IgG2a, and total IgE. L. mexicana-
specific immunoglobulin G1 (IgG1) and IgG2a in the plasma of infected mice
were detected by ELISA as previously described (1, 23). Briefly, Immulon 1B
flat-bottomed microtiter plates were coated with 100 l 10 g/ml L. mexicana
lysate (lysate was prepared as previously described [23]) in PBS (pH 9.0) over-
night at 4°C. Plasma samples were serially diluted in duplicate, followed by a 1-h
incubation at 37°C. Bound Leishmania-specific antibodies were detected with a
1-h incubation with horseradish peroxidase-conjugated goat anti-mouse IgG1
(Southern Biotechnology Associates Inc., AL) or horseradish peroxidase-conju-
gated goat anti-mouse IgG2a (Southern Biotechnology Associates Inc., AL). The
substrate tetramethylbenzidine in pH 5.5 sodium acetate buffer containing
0.0003% hydrogen peroxide (BDH, Poole) was then added to the wells, and
following color development, the reaction of the substrate with the conjugated
horseradish peroxidase was stopped by the addition of 10% sulfuric acid to the
wells. The absorbance was then measured at 450 nm using a plate reader with
SOFTmax PRO software (Molecular Devices), and the endpoint dilution was
determined. Total IgE in the plasma of infected mice was detected by capture
ELISA as previously described (23), using R35-72 capture IgE monoclonal
antibody (PharMingen) and biotinylated rat anti-mouse IgE (Southern Biotech-
nology Associates). Antibody titers were compared using the Mann-Whitney U
test, and all other comparisons were made using the Student t test.
IFN- depletion and parasite enumeration. In vivo depletion of IFN- was
achieved by the intraperitoneal inoculation of 150 g rat hybridoma R4-6A2
(PharmMingen) on day 0 and on days 4 and 8 postinfection of mice with 5  106
L. mexicana amastigotes into the footpad. Three animals comprised each exper-
imental group, and four samplings were taken from each footpad. Parasite
numbers were quantified by limiting dilution as previously described (6).
RESULTS
Western blot analysis of ICP mutant L. mexicana stationary-
phase promastigotes. ICP null mutants were produced as de-
scribed previously (3), and two independent clones (icp1 and
icp3 mutants) were isolated. The two clones were used for
producing ICP overexpressing cell lines (icp1[pXG ICP] and
icp3[pXG ICP]), whereas clone 1 only was used to produce a
cell line reexpressing the protein from a single ICP copy inte-
grated in its genome (icp::PrRNAICP). The expression of ICP
in stationary-phase promastigotes from wild-type and trans-
genic L. mexicana cell lines was assessed by Western blot
analysis (Fig. 1). This confirmed that no ICP was present in
icp1 and icp3 promastigotes. Expression of ICP in the icp::
PrRNAICP mutant was similar to that in the wild type, whereas
icp1[pXG ICP] and icp3[pXG ICP] had a significantly
higher level of ICP expression (5-fold increase) (Fig. 1).
L. mexicana mutants overexpressing ICP have significantly
reduced virulence for BALB/c mice. Rapidly growing, nonheal-
ing lesions were induced following inoculation of BALB/c mice
with 5  105 wild-type, icp1, and icp3 stationary-phase pro-
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mastigotes into the hind footpad (Fig. 2a). However, lesion
growth was significantly (P 	 0.05) reduced, from week 8
postinfection, following inoculation with icp1 and icp3 par-
asites compared with that following inoculation with wild-type
parasites. Reexpression of the ICP gene with the integrative
construct restored some virulence, and 10 weeks elapsed be-
fore a significant difference in lesion growth kinetics was ob-
served between BALB/c mice infected with icp::PrRNAICP
and those infected with wild-type parasites. Overexpression of
ICP resulted in a significant change in disease phenotype:
BALB/c mice inoculated with icp3[pXG ICP] stationary-
phase promastigotes developed small lesions which ceased to
grow after week 5, while those infected with icp1[pXG ICP]
stationary-phase promastigotes apparently resolved infections
by week 13. Significantly reduced parasite burdens were also
found in the lesions at 13 weeks postinfection of the BALB/c
mice infected with icp1, icp3, icp3[pXG ICP], and icp::
PrRNAICP parasites relative to the parasite burden for those
infected with wild-type parasites (Fig. 2b). No parasites could
be detected nor promastigotes derived from the site of infec-
tion with icp1[pXG ICP] stationary-phase promastigotes.
When possible, lesion-derived icp3[pXG ICP] parasites were
differentiated back to promastigotes in vitro without selective
pressure and tested for ICP expression by Western blotting.
Surprisingly, and in spite of the absence of antibiotic selection
within the animal (which could lead to a loss of the plasmid
expressing ICP), 70% of the clones still expressed ICP, al-
though at a level greatly reduced from the initial level (data not
shown). When these parasites were used to infect mice, still in
the absence of selection, they were able to produce lesions
(data not shown), possibly due to their lowered ICP expression
levels. Indeed, as discussed in our previous work (3), differ-
ences in virulence could be due to variations in ICP expression
level between the cell lines. Indeed, wild-type ICP protein is
downregulated in amastigotes (22), whereas the integrated re-
expressing mutant icp::PrRNAICP has a constitutive expres-
sion throughout the stages. Hence, both cell lines have similar
ICP expression levels in promastigotes, but in differentiated
amastigotes the protein is likely to be slightly overexpressed in
icp::PrRNAICP compared to the level in the wild type.
BALB/c mice infected with L. mexicana mutants overex-
pressing ICP develop a modified, Th1/Th2-biased response. At
the termination of the experiment at week 13, no significant
differences in L. mexicana-specific IgG1 or IgG2a levels were
displayed in BALB/c mice inoculated with the icp1 mutant,
the icp3 mutant, or icp::PrRNAICP compared with the levels
displayed in BALB/c mice inoculated with 5  105 wild-type
stationary-phase promastigotes (Fig. 3a). However, infection
with icp1[pXG ICP] and icp3[pXG ICP] resulted in signif-
icantly (P 	 0.05) lower levels of L. mexicana-specific IgG1
than did infection with wild-type parasites. Infection with
icp1[pXG ICP] also resulted in significantly (P 	 0.05) lower
levels of IgG2a than did infection with wild-type parasites (Fig.
3a). Similarly, no significant difference was noted in the total
IgE levels for BALB/c mice infected with the icp1 mutant, the
icp3 mutant, or icp::PrRNAICP compared with the levels for
BALB/c mice inoculated with 5  105 wild-type stationary-
phase promastigotes, whereas ICP overexpressing cell lines
produced significantly (P 	 0.05) lower levels of IgE than did
wild-type parasites (Fig. 3b). In addition, IgE levels were nor-
malized against levels for noninfected control sera, and absor-
bances of greater than three times the level for the control sera
were deemed indicative of significant IgE production. This
revealed that while five of five BALB/c mice infected with
wild-type parasites or icp::PrRNAICP and four of five mice
infected with the icp1 or icp3 mutant had elevated IgE
production, only one of five of those mice infected with
icp1[pXG ICP] or icp3[pXG ICP] had raised IgE levels. In
vitro stimulation with L. mexicana antigenic lysate induced
significantly (P 	 0.05) increased levels of IFN- from spleno-
cytes isolated from BALB/c mice inoculated with icp1[pXG
ICP] or icp3[pXG ICP] in comparison with levels for the
BALB/c mice inoculated with wild-type L. mexicana (Fig. 3c).
In contrast, anti-CD3-induced IL-4 production was signifi-
cantly less (P 	 0.05) from splenocytes isolated from BALB/c
mice inoculated with icp1[pXG ICP] or icp3[pXG ICP] than
FIG. 1. Western blot analysis of whole-cell lysates prepared from wild-type (WT), icp1, icp3, icp1[pXG ICP], icp3[pXG ICP], and icp::
PrRNAICP stationary-phase L. mexicana promastigotes by using affinity-purified antisera raised against ICP and monoclonal antibodies raised
against elongation factor 1 (used as an internal loading control). The equivalent of 5  106 parasites was loaded per lane for sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and molecular masses of the proteins of interest are indicated on the right.
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from splenocytes isolated from BALB/c mice inoculated with
wild-type L. mexicana (Fig. 3d). No significant differences in
IFN- and IL-4 production (Fig. 3c and d) were detected in the
splenocytes isolated from the BALB/c mice infected with the
icp1 mutant, the icp3 mutant, or icp::PrRNAICP compared
with the levels for BALB/c mice inoculated with wild-type
parasites.
Vaccination with L. mexicana mutants overexpressing ICP
fails to protect BALB/c mice against challenge with wild-type
parasites. As infection with icp1[pXG ICP] stationary-phase
promastigotes induced a diminished type 2 and an enhanced
type 1 response in BALB/c mice, which were also able to
control infection with this mutant, the vaccine potential of
icp1[pXG ICP] was assessed. Consequently, at 14 weeks after
vaccination with icp1[pXG ICP], BALB/c mice were chal-
lenged, along with naïve, sex- and age-matched counterparts,
with wild-type L. mexicana metacyclic promastigotes. How-
ever, subcutaneous vaccination of BALB/c mice with 2  105
icp1[pXG ICP] parasites 14 weeks prior to challenge inocu-
lation did not induce resistance to infection with wild-type L.
mexicana metacyclic promastigotes. No significant difference
was noted in lesion development for vaccinated BALB/c mice
infected with wild-type parasites in the contralateral footpad
compared with that for similarly infected nonvaccinated
BALB/c mice (Fig. 4a). Similarly, prior vaccination with
icp1[pXG ICP] L. mexicana promastigotes did not alter the
parasite burdens for the BALB/c mice at the termination of the
experiment compared with those for infected, nonvaccinated
BALB/c mice (Fig. 4b). There were also no differences in the
immune responses between vaccinated and nonvaccinated
BALB/c mice at the termination of the challenge infection
(data not shown). Vaccination of BALB/c mice with icp3[pXG
ICP] stationary-phase promastigotes also failed to induce protec-
tion against wild-type challenge (data not shown).
Vaccination with L. mexicana mutants overexpressing ICP
protects C3H and C57BL/6 mice against challenge with wild-
type parasites. Previously, we have shown that other L. mexi-
cana-susceptible mouse strains are more responsive to vacci-
nation with CP mutants than BALB/c mice (2, 5). In addition,
other mouse strains, such as C3H and C57BL/6, were able to
control lesion growth with mutants that continued to cause
nonhealing disease, albeit limited, in BALB/c mice (2, 6). Con-
sequently, infection of these mouse strains with icp3[pXG
ICP] and, to a lesser extent, icp1[pXG ICP] resulted in con-
trol of lesion growth. In a typical experiment, in contrast to the
nonhealing response of C3H mice infected with wild-type par-
asites, mice infected with icp3[pXG ICP] developed small
lesions that peaked at 4 to 6 weeks and consequently pro-
ceeded to heal (Fig. 5a). Parasite burdens were similar for
wild-type- and icp3[pXG ICP]-infected mice up to 1 week
postinfection (Fig. 5b). However, by week 2 postinfection par-
asite burdens were approaching 3 orders of magnitude greater
than those for mice infected with icp3[pXG ICP] (P 	 0.01).
However, treatment of icp3[pXG ICP]-infected mice with
neutralizing IFN- resulted in a significant increase in mutant
parasite growth, also approaching 3 orders of magnitude
greater (Fig. 5b). This not only confirmed the ability of
icp3[pXG ICP] to multiply within the host but also confirmed
that growth was limited due to the generation of IFN-. Neu-
tralizing IFN- also increased icp3[pXG ICP] growth in
BALB/c mice, indicating that the role of IFN- in protection
was independent of the mouse strain used (data not shown).
Consequently, we studied the ability of ICP overexpressing
mutants to protect C3H and C57BL/6 mice against challenge
with wild-type parasites. Lesions were smaller in both
icp1[pXG ICP]- and icp3[pXG ICP]-vaccinated C3H and
C57BL/6 mice at the termination of the experiment, at week
10, than in nonvaccinated mice following challenge with 5 
105 wild-type stationary-phase promastigotes (Fig. 6a and b).
However, only in C57BL/6 mice vaccinated with icp3[pXG
ICP] was this difference significant (P 	 0.05). No increase in
lesion growth was detected from 5 weeks after challenge in-
fection in vaccinated C3H mice, whereas continuous significant
lesion growth was noted for the nonvaccinated challenged
FIG. 2. (a) Mean increases in lesion diameter for BALB/c mice
following subcutaneous infection into the hind footpad with 5  105
wild-type (f), icp1 (), icp3 (F), icp1[pXG ICP] (E), icp3[pXG
ICP] (Œ), and icp::PrRNAICP (‚) L. mexicana stationary-phase pro-
mastigotes. (b) Mean numbers of parasites isolated at week 13 postin-
fection from BALB/c mice infected with 5  105 wild-type (WT),
icp1, icp3, icp1[pXG ICP], icp3[pXG ICP], and icp::PrRNAICP
L. mexicana stationary-phase promastigotes (* P 	 0.05; **, P 	 0.01;
***, P	 0.005). ND, not detected. Bars represent standard errors (se)
of the means. Results are representative of three independent exper-
iments.
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group. Control of the challenge infection due to prior vacci-
nation of C3H mice with icp1[pXG ICP] or icp3[pXG ICP]
and C57BL/6 mice with icp3[pXG ICP], though not
icp1[pXG ICP], stationary-phase promastigotes was also
demonstrated by the significantly (P 	 0.05) reduced parasite
burdens compared with those for nonvaccinated mice infected
with 5  105 wild-type promastigotes (Fig. 6c and d). Subcu-
taneous vaccination of C3H and C57BL/6 mice with 2  105
icp3[pXG ICP] or icp1[pXG ICP] parasites 14 weeks prior
to inoculation with wild-type parasites resulted, at the termi-
nation of this experiment, in a significantly (P 	 0.05) higher
increase in antigen-induced IFN- production from spleno-
cytes than in antigen-induced IFN- production from spleno-
cytes of naïve C3H or C57BL/6 mice infected with 5  105
wild-type L. mexicana stationary-phase promastigotes (Fig. 6e
and f).
DISCUSSION
Previous studies of the characterization and function of L.
mexicana ICP have suggested that it may play a role in pro-
tecting the parasite from the degradative activity of not only
parasite CPB and CPA in particular but also host CPs which
are found colocalized with ICP in the parasite endocytic vesi-
cles (3). Consequently, ICP-deficient L. mexicana mutants lose
some virulence for BALB/c mice, as measured by slightly re-
duced lesion growth, which was somewhat restored by reex-
pressing normal levels of ICP in the mutants (3). In spite of the
reduced virulence of the icp mutant, there are no discernible
immunological consequences for the host or parasite, as dem-
onstrated in the present study by antibody levels as well as
IFN- and IL-4 production. In contrast, we demonstrate not
only that parasites overexpressing ICP have greatly reduced
virulence for mice but also that this is associated with a switch
from a Th2- to a Th1-biased response. Consequently, when
ICP is overexpressed by mutant parasites, it influences the
infectivity of the parasite in ways other than those merely
associated with efficient housekeeping and fitness activities.
Our previous studies utilizing mutants of L. mexicana defi-
cient in the CPs have revealed the importance of both clan CA,
family C1 peptidases CPB and CPA for virulence. cpb mutant
amastigotes, although equally as infective for macrophages in
vitro as wild-type parasites (10), have a reduced ability to
induce lesion growth in BALB/c mice (2, 8). cpa cpb mu-
tants were less infective for BALB/c mice than cpb mutants
(2, 18), which also implicates CPA as a virulence factor. As ICP
has been shown to preferentially inhibit clan CA, family C1,
FIG. 3. L. mexicana-specific IgG1 and IgG2a levels (a) and total IgE levels (b) in BALB/c mice in response to infection with 5  105 wild-type
(WT), icp1, icp3, icp1[pXG ICP], icp3[pXG ICP], and icp::PrRNAICP stationary-phase promastigotes into the hind footpad (*, P 	 0.05;
**, P 	 0.01). In vitro production of IFN- (c) and IL-4 (d) by splenocytes, in the presence of 10 g/ml L. mexicana antigen and 0.5 g/ml
anti-CD3, respectively, from BALB/c mice infected with 5  105 wild-type, icp1, icp3, icp1[pXG ICP], icp3[pXG ICP], and icp::PrRNAICP
L. mexicana stationary-phase promastigotes at week 13 postinfection (*, P 	 0.05). Bars represent standard errors of the means. Results are
representative of three independent experiments.
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cathepsin L-like peptidases, such as CPB (22), and to bind
specifically to CPA and CPB (3), this could be the likely mech-
anism by which ICP overexpressing mutants lose virulence.
Although expressed primarily in wild-type promastigotes rather
than amastigotes (22), ICP is released in significant quantities by
the amastigotes of overexpressing clones icp1[pXG ICP] and
icp3[pXG ICP] (3). The virulence of L. mexicana for BALB/c
mice has been associated with the ability of CPB/CPA to in-
duce a Th2 response in BALB/c mice. In infected mice, cpb
and cpa cpb mutants induce a Th1 response characterized
by increased IFN- production, and consequently, lesion
growth is inhibited (2, 5). Similar immunological and disease
phenotypes were found in mice infected by ICP overexpressing
mutants in the present study, suggesting that ICP acts to inhibit
CPB/CPA immunomodulatory activity.
Small chemical inhibitors of clan CA CPs have previously
been shown to inhibit the growth of several species of Leish-
mania, including L. donovani (7), L. chagasi (11, 15, 26), L.
tropica (15), and L. major (14, 21), and a number of mecha-
nisms have been implicated. However, ICPs may not necessar-
ily operate by targeting parasite CPs directly but may act by
inhibiting the crucial role of host CPs in the processing of
antigen via major histocompatibility complex (MHC) class II.
For example, studies have shown that chemically inhibiting
cathepsins B, which are involved in antigen processing,
switches L. major-infected BALB/c mice from producing a
nonhealing Th2 to a healing Th1 response (14), while inhibit-
ing cathepsins L promotes a Th2 response and increased sus-
ceptibility to the parasite (19, 29). However, ICP preferentially
binds and inhibits mammalian cathepsin L and has 1/1,000 less
affinity for cathepsin B (22). Consequently, this specificity
probably negates a role for ICP from overexpressing mutants
in directly modulating host cell antigen-presenting pathways.
However, L. mexicana and L. amazonensis CPs have been
implicated in the inhibition of antigen presentation by degrad-
ing MHC class II molecules in the parasitophorous vacuole (9).
ICP in overexpressing mutants in this study could therefore
function to promote MHC class II antigen presentation indi-
rectly by inhibiting the degradative activity of parasite CPs.
Inhibitors of cathepsin L-like CPs have also been associated
with modulating host cell production of nitric oxide upon in-
fection with L. donovani (7) or L. major (21), production of
tumor necrosis factor alpha upon infection with L. major (21),
and production of IL-12 upon infection with L. major (21) or
FIG. 4. Mean increases in hind-footpad diameter (a) and parasite
burdens (b) following subcutaneous infection with 5 105 L. mexicana
stationary-phase promastigotes into naïve BALB/c mice and BALB/c
mice vaccinated with icp1[pXG ICP]. Bars represent standard errors,
and results are representative of three independent experiments.
FIG. 5. (a) Mean increases in hind-footpad thickness for C3H mice infected with wild-type (WT) and icp3[pXG ICP] promastigotes. (b) The
parasites in the footpad were quantified by limiting dilution for up to 2 weeks postinfection, and the effects of intraperitoneal anti-IFN- treatment
(150 g rat hybridoma R4-6A2 on day 0, day 4, and day 8) on the growth of icp3[pXG ICP] were assessed. Bars represent standard errors of the
means. Results are representative of two independent experiments.
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L. mexicana (6). All of these products are associated with, or
would promote, a Th1 response and protection. There is strong
evidence that L. mexicana effects on host cell IL-12 production
are, in part, a consequence of CPB degrading host cell NF-
B
signaling pathways and that this degradation does not occur
upon infection with cpb mutant parasites or in the presence
of cell-permeable CP inhibitors (6). Overexpressed ICP could
inhibit this previously characterized CPB activity, and in addi-
tion, it could be released into the extracellular milieu (3), as
previously demonstrated for CPB (12). Hence, ICP could in-
hibit the ability of the CP to generate IL-4 and a Th2 response
(20).
FIG. 6. Mean increases in hind-footpad diameter (a and b) and parasite burdens (c and d) following subcutaneous infection with 5  105
wild-type L. mexicana stationary-phase promastigotes into naïve (f) C3H mice (a and c) and C57BL/6 mice (b and d) and mice vaccinated with
2  105 stationary-phase icp1[pXG ICP] () or icp3[pXG ICP] (F) promastigotes (a, b, c, and d). Mean levels of IFN- production from
antigen-stimulated splenocytes isolated from wild-type-L. mexicana-infected naïve C3H (e) and C57BL/6 (f) mice and mice vaccinated with
icp1[pXG ICP] or icp3[pXG ICP] stationary-phase promastigotes. *, P 	 0.05; **, P 	 0.01. Bars represent standard errors of the means.
Results are representative of two independent experiments.
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As infection of BALB/c mice with L. mexicana metacyclic
promastigotes of overexpressing clones icp1[pXG ICP] and
icp3[pXG ICP] induced immune responses that favor resis-
tance to infection, these genetically modified parasites were
considered as vaccine candidates. icp1[pXG ICP] was consid-
ered the most suitable candidate for the development of a
vaccine, as this mutant induced no detectable lesion progres-
sion or parasite replication. However, subcutaneous vaccina-
tion with icp1[pXG ICP] did not confer protection to subse-
quent challenge with wild-type L. mexicana promastigotes. No
significant differences in lesion development or parasite bur-
dens or subsequent immune responses were detected (data not
shown) following infection of vaccinated mice with wild-type
parasites or infection of naïve mice. Significantly, we have
demonstrated previously that only limited resistance was con-
ferred on BALB/c mice vaccinated with cpa cpb mutant
parasites and that this required extremely large experimental
groups of 20 mice to demonstrate (2). However, while the
nonhealing responses of BALB/c mice for L. mexicana have
been related to CP-induced IL-4 (8, 20), by contrast, the vir-
ulence of L. mexicana for the L. major-resistant C3H and
C57BL/6 strains has been associated with the ability of CPB to
inhibit Th1 responses rather than to induce Th2 responses (5).
In mice infected with the L. mexicana cpb mutant, lesion
resolution was associated with elevated Th1 responses, and
healing was demonstrated to be Th1 dependent. Prior vacci-
nation of these mice as well as CBA mice (2, 5) with cpb
mutant parasites afforded significant protection against chal-
lenge with wild-type parasites. Similarly, vaccination of
C57BL/6 and C3H mice with icp3[pXG ICP] and vaccination
of C3H mice with icp1[pXG ICP] or icp3[pXG ICP] did
offer some protection against wild-type challenge, as demon-
strated by elevated antigen-induced spleen cell IFN- produc-
tion, delayed lesion growth, and reduced parasite numbers.
Overall, this study not only confirms the role of L. mexicana
cathepsin L-like CPs as virulence factors but also provides further
evidence of the therapeutic potential of specific CP inhibitors.
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